A five-year forward view of market size, competitive structure, reimbursement pressure, and the strategic moves that will decide who wins.
Interventional pain management enters 2026 as a large, structurally growing, and unusually unstable market. Demand has never been stronger. The Centers for Disease Control and Prevention reports that 24.3% of U.S. adults lived with chronic pain in 2023 and 8.5% with high-impact chronic pain, up from 20.9% and 6.9% in 2021. Aging Sunbelt populations, the collapse of opioid-first prescribing, and payer appetite for durable, non-pharmacological outcomes all point in the same direction.
The instability is on the payment side, not the demand side. Coherent Market Insights values the global interventional pain management market at $73.24 billion in 2025 and projects $108.48 billion by 2032 at a 6.5% CAGR. Mordor Intelligence sizes the broader pain management market at $85.63 billion in 2026, reaching $106.86 billion by 2031 at 4.53%. Straits Research lands close, at $85 billion in 2026. These figures use different scope boundaries and should be read as a corridor, not a point. Interpolating the Coherent series, the interventional segment enters 2026 at roughly $78 billion.
Our base case puts the market at approximately $107 billion by 2031, a 6.5% CAGR. The directional verdict is moderate-to-strong growth with a violent internal reallocation. Devices are the engine: Grand View Research projects pain management devices growing at 9.4% to 9.5% CAGR to $13.16 billion by 2030, while pharmacological products, still 68.92% of 2025 revenue per Mordor, grow at roughly a third of that rate. Orthobiologics grow faster still, with Mordor placing platelet-rich plasma at a 12.18% CAGR through 2030, but almost entirely outside insurance.
The single most consequential development of the forecast window is regulatory, not technological. CMS finalized a -2.5% efficiency adjustment for calendar year 2026 that touches more than 7,000 non-time-based CPT codes, explicitly naming interventional pain management. It also revalued indirect practice expense by site of service. Per the American Society of Interventional Pain Physicians, facility-based interventional pain physicians face roughly an 11% reimbursement decrease while office-based physicians see roughly a 7% to 10% increase. From January 1, 2027, the mandatory Ambulatory Specialty Model puts low back pain specialists on payment adjustments of -9% to +9% with an 85% redistribution percentage. Washington is not shrinking the market. It is deciding where in the market the profit sits, and it is choosing the office.
Interventional pain management is the procedure-based treatment of chronic and refractory pain by targeting the pain generator directly, rather than blunting the signal systemically with drugs. It is practiced overwhelmingly by fellowship-trained anesthesiologists and physical medicine and rehabilitation physicians in office settings, ambulatory surgery centers, and hospital outpatient departments.
This report scopes the sector across four procedure families:
Analgesic pharmaceuticals, physical therapy, and open spine surgery sit adjacent. They are treated here as substitutes and referral partners, not as part of the addressable market. Note that several published "interventional pain management" market figures, including the widely cited Coherent Market Insights series, use a broader boundary that absorbs drug and device revenue. Where that matters, we say so.
Market-sizing in this sector is genuinely contested, and the disagreement is definitional rather than analytical. Four independent estimates frame the corridor:
| Source | Scope | Current Size | Forecast |
| Coherent Market Insights | Interventional pain management, global (broad) | $73.24B (2025) | $108.48B by 2032, 6.5% CAGR |
| Mordor Intelligence | Pain management, global (all modalities) | $85.63B (2026) | $106.86B by 2031, 4.53% CAGR |
| Straits Research | Pain management, global | $85B (2026) | $110B by 2034, 4.5% CAGR |
| The Business Research Company | Pain management, global | $80.93B (2026) | $96B by 2030, 4.4% CAGR |
| Grand View Research | Pain management devices only | $8.42B (2025) | $13.16B by 2030, 9.4% CAGR |
| Market Data Forecast | Pain management, U.S. only | $32.31B (2026) | $42.87B by 2034, 3.6% CAGR |
| IBISWorld | U.S. pain management physicians (services) | $64.1B (2024) | Reported +0.66% year over year |
Two observations matter more than the headline numbers. First, the device-and-procedure core of this sector is roughly a tenth the size of the headline "pain management" figure, but is growing at roughly double the rate. Grand View Research puts neurostimulation at 57.7% of device revenue in 2024 and North America at 47.6% of the device market. Second, the U.S. services layer is where the economics actually live. IBISWorld sized U.S. pain management physicians at $64.1 billion in 2024, and that revenue is what the 2026 fee schedule reprices.
A reasonable mid-point estimate for the interventional segment entering 2026, interpolating the Coherent series and sanity-checking against Mordor and Straits, is approximately $78 billion globally. That is the anchor used for the Section 4a projections. It is an estimate, not a published figure, and should be treated accordingly.
[IMAGE SUGGESTION: Column chart of interventional pain management market size, 2026 to 2031, base case ($78B rising to $107B), with a shaded band showing the published estimate corridor from Coherent Market Insights (high) and Mordor Intelligence (low). Source: Section 2b table and Section 4a projections.]
Prevalence is rising, not plateauing. Per CDC National Center for Health Statistics data, chronic pain among U.S. adults climbed from 20.4% in 2016 to 20.9% in 2021 to 24.3% in 2023. High-impact chronic pain reached 8.5%. See the NCHS Data Brief No. 518 for the full breakdown. This is the rarest thing in healthcare markets: a demand curve that is steepening rather than flattening.
Demographics compound it. Mordor Intelligence notes prevalence peaks in the 65-plus cohort, and Grand View Research cites CDC projections of 78 million U.S. adults with arthritis by 2040. The Straits Research and Mordor analyses both attribute North American dominance, roughly 38% of global revenue in 2025, to surgical volume and healthcare spending rather than prevalence alone.
Opioid displacement is the second driver, and it is now policy rather than sentiment. The CDC 2022 Clinical Practice Guideline recommends non-opioid pharmacotherapy as first-line for chronic pain. Market Data Forecast notes that many states have implemented laws preventing step therapy that requires opioids before non-opioids. Every prescription that does not get written is a procedure that might.
Third, the site-of-care shift. Interventional procedures are migrating from hospital outpatient departments to ASCs and to the office, and CMS is now actively paying for that migration. Grand View Research identifies ASCs as the fastest-growing end-use segment in orthopedic regenerative products.
Fourth, consumer-funded longevity demand. This is the newest driver and the least measured. Affluent, active patients in their forties through sixties are buying joint preservation as a lifestyle good, not a medical necessity, and paying cash. Mordor cites typical PRP pricing of $500 to $2,000 per session, with most insurers classifying it as elective.
The sector runs on four distinct economic models, and they are diverging fast.
| Headwind | Severity | Detail |
| CMS -2.5% efficiency adjustment | High | Finalized October 31, 2025, for CY2026. Applies to work RVUs for non-time-based services across 7,000-plus CPT codes. CMS explicitly named interventional pain management. The AMA notes it blunts or reverses the 2.5% One Big Beautiful Bill increase for many specialists. |
| Site-of-service practice expense revaluation | High | Per ASIPP, facility-based interventional pain physicians face roughly -11%; office-based practices gain roughly +7% to +10%. Asymmetric, not uniform. ASCs were grouped with hospitals despite being physician-owned. |
| Ambulatory Specialty Model (mandatory 2027) | High | Low back pain specialists face 9% to +9% adjustments from 2029, with an 85% redistribution percentage designed to net out as Medicare savings. CMS declined ASIPP-requested changes. |
| No payer coverage for orthobiologics | High | PRP and most regenerative injections are classified as elective. Multiple sessions at $500 to $2,000 each cap penetration to households that can self-fund. |
| FDA and FTC enforcement on regenerative claims | Medium-High | Ninth and Eleventh Circuit rulings have narrowed the same-surgical-procedure exception. The FDA issued multiple 2026 warning letters on exosome marketing. FTC has separately pursued clinics on promotional-claim grounds. |
| Opioid-era reputational overhang | Medium | Physician Growth Partners attributes the specialties’ below-average consolidation partly to proximity to the opioid epidemic and reimbursement volatility. |
| Workforce and access constraints | Medium | Per the University of Washington Rural Health Research Center data, 89% of rural counties are designated Health Professional Shortage Areas for pain management, with waits exceeding 14 weeks for interventional procedures. |
| Device cost and revision burden | Medium | Mordor notes replacement surgeries every four to seven years, adding anesthesia and hospitalization charges, straining payer tolerance. |
| Non-opioid pharmaceutical substitution | Low-Medium | Journavx is approved for acute, not chronic, pain, and did not outperform hydrocodone-acetaminophen in trials. Chronic indications remain under study. |
| State scrutiny of MSO and CPOM structures | Medium | States are directly targeting the management services organization structures that private equity uses to work around the corporate practice of medicine doctrine. |
The sector has two competitive layers that rarely appear in the same analysis. The device layer is a consolidated oligopoly. The provider layer is one of the most fragmented in American medicine. Both are profiled here because the strategic questions facing each are different.
| Company / HQ | Market Position | Core Offering | Competitive Moat | Recent Moves | Growth Trajectory |
| Medtronic / Dublin, Ireland | SCS leader; ~5-8% of total pain management revenue per EinPresswire analysis | Inceptiv closed-loop SCS, intrathecal pumps, RFA | Closed-loop ECAP sensing, battery longevity, full-body 3T MRI compatibility, distribution depth | FDA clearance for Inceptiv closed-loop SCS (2024); 12-month data showing 93% of patients with reduced overstimulation and 82% with 50%+ low back pain reduction (Jan 2025) | Steady. Defending share via closed-loop differentiation |
| Boston Scientific / Marlborough, MA | Top-3 in SCS; leader in vertebrogenic pain | WaveWriter SCS, Intracept basivertebral nerve ablation | Multi-waveform versatility; only BVN ablation platform; expanded non-surgical low back pain indication | Acquired Relievant Medsystems (March 2024); FDA approval to extend WaveWriter to non-surgical low back pain (Feb 2024); CE mark and European launch of Intracept (July 2025) | Strong. Widening the addressable pool beyond post-surgical patients |
| Abbott / Abbott Park, IL | Top-3 in SCS; leader in burst and DRG | Proclaim XR, Eterna, NeuroSphere platform | Burst and DRG stimulation IP; recharge-free platforms; St. Jude Medical installed base | Launched Eterna SCS with Xtend energy technology, requiring as few as five charges per year (Jan 2025); telehealth alliance boosting NeuroSphere usage | Steady. Competing on patient burden reduction |
| Globus Medical / Audubon, PA | Challenger acquired the high-frequency franchise | Nevro HFX 10 kHz SCS, spinal surgery portfolio | Only player combining surgical spine and neuromodulation under one roof; 10 kHz paresthesia-free IP | Acquired Nevro Corp for $250 million (February 2025); Nevro had previously acquired Vyrsa Technologies for sacroiliac joint pain and secured CE mark for HFX iQ (Nov 2024) | Uncertain. Integration risk against a distressed acquisition price |
| Vertex Pharmaceuticals / Boston, MA | New entrant; substitute rather than participant | Journavx (suzetrigine), NaV1.8 pain signal inhibitor | First new class of pain medicine approved in over 20 years; no addictive potential | FDA approval January 30, 2025; more than 550,000 prescriptions written and filled by the end of 2025; chronic pain and diabetic peripheral neuropathy studies ongoing | Strong. Visible Alpha projects $362M in 2026 sales, rising toward $2.6B peak by 2032 |
| Arthrex / Naples, FL | Leader in orthobiologics kits | PRP preparation systems, sports medicine biologics | Surgeon relationships, procedural training networks, and breadth of MSK portfolio | Competing against Terumo’s FDA-cleared automated PRP system (May 2025) and Zimmer Biomet’s single-use in-office PRP kit (March 2025) | Strong. Riding a 12.18% PRP segment CAGR per Mordor |
| American Pain Consortium / U.S. (PE-backed) | Leading provider platform | National network of interventional pain practices and ASCs | Scale in payer contracting, centralized revenue cycle, and ASC ownership | Acquired Pain Treatment Center of the Bluegrass, Lexington, KY (May 2026), backed by Discovery Capital, Cedar Pine, and Peakline Partners | Strong. Buying into a fragmented specialty early |
| CPIhealth / Austin, TX (PE-backed) | Regional roll-up platform | Interventional pain clinics plus surgical centers | Iron Path Capital backing; density strategy in Texas, Indiana, and Colorado | Acquired Midwest Interventional Spine Specialists and Serenity Surgical Center (April 2026) | Strong, but exposed to the facility-side reimbursement cut |
[IMAGE SUGGESTION: Two-panel competitive positioning visual. Panel 1: SCS market share concentration, showing Medtronic, Abbott, Boston Scientific, and Nevro at roughly 75% of worldwide sales per Mordor Intelligence. Panel 2: provider-side fragmentation, showing ~15-20 PE platforms in pain management versus 60-plus deals in gastroenterology since 2021, per Physician Growth Partners. Source: Section 3a research.]
Integrated Spine, Pain & Wellness (ISPW) is a physician-led, concierge regenerative medicine and interventional pain practice at 7425 East Shea Boulevard in Scottsdale, Arizona, founded and led by Dr. Ashu Goyle. It is a useful case study precisely because it occupies the segment this report identifies as structurally advantaged and commercially exposed at the same time.
What they do. ISPW combines conventional interventional pain medicine, spinal injections, radiofrequency ablation, neuromodulation, and musculoskeletal joint injections, with a regenerative and longevity layer: the Regenokine Program, bone marrow aspirate concentrate, platelet-rich plasma, MLS M7 laser therapy, IV wellness, anti-inflammatory nutrition, and a VIP concierge tier. The practice positions itself around joint longevity rather than symptom suppression, under the promise "Not Managing Pain, Healing It."
Sub-segment and positioning. ISPW sits in the premium, physician-delivered, largely self-funded corner of the orthobiologics market. That corner is growing at roughly 12% per year per Mordor Intelligence, faster than any insurance-billed procedure family in this report, and it is also the corner with the least payer support and the most enforcement scrutiny.
Differentiation and moat. Three elements are genuinely defensible. First, credentials: Dr. Goyle is a double board-certified, fellowship-trained anesthesiologist and interventional pain specialist whose pain medicine fellowship was at the Cleveland Clinic. In a segment where the dominant scaled competitor is a franchise system that a competing network publicly characterizes as relying on part-time medical directors and mid-level delivery, physician-delivered care is a real, communicable difference. Second, exclusivity: ISPW positions itself as Arizona’s exclusive Regenokine provider, a supply-side lock that franchise models cannot replicate by opening another unit. Third, model: the Functional Spinal Unit approach treats joints as complete functional units and addresses supporting structures, which is a clinical philosophy rather than a procedure menu, and philosophies are harder to copy than injections.
Market fit. ISPW’s two stated buyer profiles, the "Active Ageless Athlete" (ages 40 to 65-plus, $150,000-plus income, golf, pickleball, and tennis, frustrated by cortisone cycles and unwilling to accept surgery) and the "Health-Conscious Professional" (ages 35 to 55, $200,000-plus income, longevity and biohacking oriented, skeptical of one-size-fits-all medicine), map onto Scottsdale with unusual precision. Scottsdale’s median age is 49, and its median household income is $110,886, with roughly 64,452 seniors among 209,812 adults. Arizona is 19.3% aged 65-plus, and Maricopa County added 57,471 residents between July 2023 and July 2024, the third-largest numeric county gain in the United States. The catchment is not just wealthy. It is aging into the exact conditions ISPW treats.
Why are they positioned to win?The 2026 fee schedule is, on balance, a tailwind for this practice. CMS revalued indirect practice expense by site of service; per ASIPP, office-based interventional pain practices see roughly a 7% to 10% increase while facility-based ones see roughly an 11% decrease. ISPW is office-based. Its self-pay and concierge revenue is structurally immune to the -2.5% efficiency adjustment and to the Ambulatory Specialty Model’s -9% to +9% swing. Meanwhile, the FDA and FTC enforcement wave against exosome marketing and unsubstantiated regenerative claims is an advantage, not a threat, for a practice whose stated brand rules include being honest about timelines, costs, and realistic outcomes and never guaranteeing results. Compliance discipline is becoming a competitive asset in this segment, and most of the segment does not have it.
What they must do. The honest constraints are structural. ISPW is a single-site practice built around a single named physician, which concentrates both brand equity and clinical capacity in one person and caps scale without dilution of the very thing that differentiates it. Its fastest-growing service lines have no insurance reimbursement, which means patient acquisition cost is a permanent line item rather than a launch expense, and PE-backed and franchised competitors can outspend it on media in any given quarter. QC Kinetix’s 2024 contraction demonstrates that marketing-led scaling in this segment fails when spend outruns delivered outcomes, which argues for ISPW’s model, but it also demonstrates how much capital competitors are willing to burn while learning that lesson. The strategic imperative over 2026 to 2031 is to convert clinical differentiation into durable, searchable, citable authority faster than better-funded competitors can convert capital into local share of voice, and to build clinical capacity that extends Dr. Goyle’s protocols without diluting the physician-delivered promise the brand rests on.
| Force | Rating | Rationale |
| Threat of new entrants | Medium | Bifurcated. Device entry is near-impossible: Boston Scientific, Medtronic, Abbott, Nevro, and Nuvectra hold roughly 95% of SCS globally behind waveform patents and PMA pathways. Clinic entry is trivially easy: QC Kinetix explicitly markets franchises to non-physicians at $250,100 to $655,080. |
| Bargaining power of suppliers | Medium | Four multinationals control roughly 75% of worldwide SCS sales per Mordor, giving implant vendors real pricing leverage over clinics. Offsetting this, hospitals increasingly sign multisource procurement contracts to hedge supply risk, opening room for challengers. |
| Bargaining power of buyers | High | CMS sets rates unilaterally and just cut 7,000-plus codes by 2.5%. Commercial payers follow. In the cash-pay segment, buyers hold near-total power: they are affluent, informed, and comparison-shopping across clinics with no switching cost. |
| Threat of substitutes | High | Physical therapy is a $56.4 billion U.S. industry across 156,000 businesses per IBISWorld. Journavx passed 550,000 prescriptions in year one. The Veterans Health Administration distributed 89,000 Quell wearable TENS units in 2023 alone, with 72% of users reporting 50%-plus pain reduction. Surgery, chiropractic, and digital therapeutics all compete for the same patient. |
| Competitive rivalry | High | Device rivalry is an innovation arms race around closed-loop control, energy density, and MR-conditional labeling, fought with outcome-based contracts. Provider rivalry is a fragmented land grab with 15-plus PE platforms and at least 21 outpatient practice acquisitions in January 2026 alone across specialties, including pain management. |
All three scenarios start from the same estimated 2026 anchor of approximately $78 billion for the global interventional segment, interpolated from the Coherent Market Insights series. The divergence is entirely about payer behavior, not patient demand.
| Scenario | 2031 Market Size | CAGR | Key Assumption |
| Bull | ~$117B | 8.5% | Closed-loop neuromodulation clears the ten-year real-world-evidence bar that health technology assessment bodies now demand, unlocking broader coverage. At least one major payer begins covering orthobiologics for knee osteoarthritis. The Ambulatory Specialty Model rewards interventionalists who demonstrate durable function gains, redirecting low back pain spending away from imaging and surgery. |
| Base | ~$107B | 6.5% | Matches the published Coherent Market Insights trajectory. Demographic demand and opioid displacement offset the CMS efficiency adjustment. Device growth near 9% and orthobiologics growth near 12% pull the blended rate above the 4.5% drug-weighted consensus. Site-of-care shift continues; the office wins share from the hospital outpatient department. |
| Bear | ~$95B | 4.0% | The efficiency adjustment is repeated rather than one-off, and the ASM’s 85% redistribution percentage nets out as sustained specialist pay cuts from 2029. Facility-based practices at -11% consolidate or exit, reducing procedure capacity. Cash-pay regenerative demand proves cyclical, as QC Kinetix’s 2024 contraction suggests it can be. Growth reverts to the drug-weighted 4.4% to 4.5% consensus of Mordor, Straits, and The Business Research Company. |
[IMAGE SUGGESTION: Grouped column chart comparing bull ($117B), base ($107B), and bear ($95B) interventional pain management market size at 2031 against the $78B 2026 anchor. Source: Section 4a table.]
The office beats the facility. This is the defining reallocation of the window. CMS cited the steady decline of private practice and the corresponding rise in hospital employment as justification for revaluing indirect practice expense by site of service. The stated concern was the duplicative payment of indirect costs to both the physician and the facility. The practical effect, per ASIPP, is roughly +7% to +10% for office-based interventional pain and roughly -11% for facility-based. Any strategy premised on ASC facility-fee capture needs rebuilding.
Procedure volume stops being the unit of value. The Ambulatory Specialty Model begins January 1, 2027, and runs through 2031, precisely the span of this forecast. It scores anesthesiology, pain management, interventional pain management, neurosurgery, orthopedic surgery, and PM&R on cost and quality for low back pain episodes, with adjustments from 2029. Practices that cannot evidence function outcomes will be paid less than practices that can, regardless of volume.
Cash-pay becomes a hedge, not a fringe. When Medicare cuts 7,000 codes and threatens -9% adjustments, revenue with no payer attached is worth a premium multiple. Expect insurance-billed practices to add regenerative and longevity lines defensively, which will intensify competition in exactly the segment ISPW occupies.
Consolidation arrives late and fast. Pain management lagged other specialties because of reimbursement volatility and opioid-era optics. That lag is closing: five notable PE transactions in the first half of 2026 alone, and platforms explicitly building density. Independent practices will face acquisition offers priced off a fee schedule that is about to change.
| Vector | Maturity | Impact Through 2031 |
| Closed-loop neuromodulation | Commercial | Medtronic Inceptiv and Saluda Evoke sense evoked compound action potentials and adjust stimulation in real time. Medtronic reported 82% of patients achieving 50%-plus low back pain reduction at 12 months. Mordor projects the device category at a 9.99% CAGR to 2031, led by closed-loop platforms. |
| AI patient selection | Early commercial | Machine learning models have outperformed lead screening trials at predicting SCS response in a multicenter study. The strategic value is avoiding the expense: better selection converts a cost center into a margin. Literature remains fragmented and mostly single-center retrospective. |
| Basivertebral nerve ablation | Commercial, scaling | Boston Scientific’s Intracept treats vertebrogenic pain, with 75% of patients reporting long-lasting improvement from a single procedure, with benefits sustained over five years. CE marked in Europe in July 2025. Opens a patient pool previously routed to fusion. |
| High-frequency 10 kHz SCS | Mature | Paresthesia-free therapy, now inside Globus Medical. Nevro’s HFX iQ with AdaptivAI received FDA approval and limited release in September 2024. The question is integration, not efficacy. |
| Automated orthobiologics preparation | Commercial | Terumo received FDA clearance for a fully automated PRP system in May 2025; Zimmer Biomet launched a single-use in-office kit in March 2025; Smith+Nephew launched CENTRIO in September 2025. Standardization attacks the biggest scientific criticism of PRP: operator variability. |
| NaV1.8 inhibitors | Commercial (acute only) | Journavx cleared 550,000 prescriptions in year one at $15.50 per 50mg tablet. Chronic pain and diabetic peripheral neuropathy programs continue. Helped diabetic neuropathy in small studies, no better than a placebo for sciatica. |
| Remote therapeutic monitoring | Commercial | CY2026 adds new RPM and RTM codes for 2 to 15 days of transmitted data and cuts the clinical time threshold for 99457 and 98980 from 20 minutes to 11-20. These are time-based codes and, therefore, are exempt from the efficiency adjustment. A rare, deliberate revenue opening. |
| Sub-Segment | Projected CAGR | Source and Note |
| Regenerative medicine (broad) | 16.8% | Grand View Research, 2025-2030, $35.47B to $90.01B. Includes cell and gene therapy well beyond MSK; treat as directional ceiling, not addressable market. |
| Platelet-rich plasma | 12.2% | Mordor Intelligence, 2025-2030, $0.73B to $1.30B. Fortune Business Insights is more conservative at 11.3%. Orthopedics and sports medicine lead; cosmetic applications grow faster at 17.85%. |
| Home-care setting | 11.6% | Mordor Intelligence, through 2031. The fastest-growing setting of care, driven by wearables and remote monitoring. |
| Pain management devices | 9.4-9.5% | Grand View Research, 2025-2030, $8.42B to $13.16B. Neurostimulation held 57.7% of 2024 device revenue; RFA is the fastest-growing product line. |
| Neuromodulation (all) | 8.6% | Mordor Intelligence, 2025-2030, $6.64B to $10.06B. Implantables held a roughly 70% share in 2024. |
| Spinal cord stimulation | 7.9% | Mordor Intelligence, 2026-2031, $3.38B to $4.94B. Fortune Business Insights is more bullish at 9.6%; Market Research Future is more cautious at 5.9%. The spread reflects coverage uncertainty. |
| Pain management (total) | 4.4-4.5% | Mordor, Straits, and The Business Research Company converge here. Drug-weighted, so it understates the interventional core. |
| Pharmacological therapies | Below market | Mordor puts drugs at 68.92% of 2025 revenue, but the slowest-growing mode. The mix shift away from drugs is the sector’s central story. |
[IMAGE SUGGESTION: Horizontal bar chart of projected CAGR by sub-segment, 2025/2026 to 2030/2031, ordered high to low: regenerative medicine 16.8%, PRP 12.2%, home care 11.6%, devices 9.4%, neuromodulation 8.6%, SCS 7.9%, total pain management 4.5%. Source: Section 4d table.]
The 2026 Physician Fee Schedule is the sector’s defining document. CMS issued the final rule on October 31, 2025, with two conversion factors for the first time: $33.57 for qualifying APM participants (up 3.77%) and $33.40 for everyone else (up 3.26%). Layered against that, the -2.5% efficiency adjustment applies to work RVUs for all non-time-based codes. Specialty groups calculate that it wipes out the congressional pay bump across more than 7,000 services. The full rule is on the CMS Physician Fee Schedule page.
The Ambulatory Specialty Model is the longer fuse. Mandatory participation begins January 1, 2027, and runs through 2031 for specialists treating low back pain or heart failure in designated core-based statistical areas. Eligibility requires having historically treated at least 20 Part B Medicare patients per year with qualifying episodes. Payment adjustments of -9% to +9% start in 2029, scored on disease management, guideline adherence, and care coordination at the individual clinician level. Critically, CMS plans an 85% redistribution percentage, which means the model is designed to produce net Medicare savings rather than being budget-neutral. ASIPP requested changes, and CMS made none.
On the regenerative side, the picture is genuinely unsettled. The FDA framework still turns on whether a product qualifies as a 361 HCT/P (minimally manipulated, homologous use, no combination with another article) or requires 351 biologics licensure. Courts have narrowed the same-surgical-procedure exception, with the Ninth Circuit holding that a stromal vascular fraction procedure did not qualify and that the resulting stem cell mixture was a drug. Simultaneously, political pressure runs the other way: HHS leadership convened a roundtable on loosening stem cell regulation, and in September 2025, the FDA released draft guidance on expedited review pathways for regenerative medicine therapies. In February 2025, the FDA’s Office of Therapeutic Products held a workshop on whether to create low- and medium-risk HCT/P categories. Meanwhile, the agency issued multiple 2026 warning letters over exosome marketing.
The strategic read for providers: assume enforcement of marketing claims tightens even if product classification loosens. FTC action, which turns on promotional accuracy rather than scientific complexity, is the faster and cheaper enforcement route, and it has been used before. Practices whose claims are conservative and evidence-linked will be advantaged relative to those that are not.
North America is the profit pool, and Asia-Pacific is the growth rate, and neither fact is likely to change by 2031. Mordor puts North America at 38.10% of 2025 pain management revenue; Grand View puts it at 47.6% of the device market in 2024; Fortune Business Insights puts North America at 74.44% of spinal cord stimulation specifically in 2025, an outlier figure that reflects how concentrated implant reimbursement is in the U.S. Asia-Pacific is forecast at a 10.55% CAGR through 2031 per Mordor, with China adding neuromodulation suites in tier-one hospitals and Japan reimbursing high-frequency therapy.
For U.S. operators, the meaningful geography is intranational. The Sunbelt retirement corridor is where prevalence, disposable income, and population inflow intersect. Maricopa County added 57,471 residents between July 2023 and July 2024, the third-largest numeric county gain in the country, and remains the fourth most populous county at 4,673,096 residents. Arizona is 19.3% aged 65-plus. Scottsdale specifically carries a median age of 49 and a median household income of $110,886. Against that, the Health Resources and Services Administration designates 89% of rural counties as Health Professional Shortage Areas for pain management, with waits exceeding 14 weeks. The access gap and the affluence concentration are the same story viewed from opposite ends.
[IMAGE SUGGESTION: U.S. map or regional bar chart showing pain management demand concentration versus supply, plotting the Sunbelt retirement corridor (AZ, FL, TX, NV) against the 89% of rural counties designated as HPSAs for pain management. Overlay Asia-Pacific 10.55% CAGR as an inset. Source: Section 4f research.]
| Risk | Probability | Impact | Detail and Mitigation |
| ASM adjustments net negative for most specialists | High | High | The 85% redistribution percentage is explicitly designed to reduce total physician payments. Mitigation: build function-outcome measurement into the workflow now, before 2029 scoring begins. |
| Efficiency adjustment repeats in CY2027 and beyond | Medium | High | CMS framed it as an ongoing methodology, not a one-time correction. AMA notes Medicare physician pay has fallen 33% inflation-adjusted since 2001. Mitigation: revenue diversification into time-based codes and cash-pay lines. |
| FDA or FTC enforcement sweep on regenerative marketing | Medium | High | A 2020 study found 96% of stem cell clinic websites contained at least one misstatement. Precedent exists: FTC v. Regenerative Medical Group settled at $525,000 within a week. Mitigation: conservative claims, documented HCT/P compliance, and evidence-linked patient education. |
| PE roll-up compresses independent practice economics | Medium | Medium | GAO found PE held about 6.5% of U.S. physicians in 2024 and rising. Platforms can outspend independents on marketing and out-negotiate them on payer contracts. Mitigation: differentiate on care model rather than price; consider a selective partnership rather than a sale. |
| State CPOM and MSO crackdown | Medium | Medium | States are directly targeting the MSO structures PE uses. Cuts both ways: it slows the roll-up threat, but chills exit valuations for sellers. |
| Device class safety action or recall | Low | High | Australia temporarily withdrew certain SCS models on safety grounds, opening the share for firms with stronger post-market surveillance. A U.S. equivalent would freeze implant volume sector-wide. |
| Journavx succeeds in chronic pain indications | Low-Medium | Medium-High | Currently acute-only, and it did not beat hydrocodone-acetaminophen in trials. Failed against placebo for sciatica. If chronic approval lands with strong data, the conservative management step before intervention gets longer. |
| BLACK SWAN: major sham-controlled RCT invalidates a flagship interventional therapy, triggering national coverage withdrawal | Low | Severe | The sector’s deepest structural vulnerability is that several high-volume procedures rest on evidence bases that payers are increasingly willing to re-litigate, while HTA bodies now demand ten-year real-world evidence. A single well-powered negative trial on epidural steroid injection or medial branch RFA, followed by a national coverage determination reversal, would remove a revenue pillar in under 24 months with no substitute capacity. Mitigation: portfolio breadth across procedure families, and participation in registry evidence generation rather than waiting to be measured by someone else. |
Stop selling implants and start selling avoided explants. The economic argument that persuades a payer in 2029 is not waveform superiority; it is durable function at lower total cost of care. That means the AI patient-selection layer is not a feature; it is the business case: machine learning models have already outperformed lead screening trials at predicting SCS response, and the literature’s weakness is that studies are retrospective and single-center. Whoever funds the prospective multicenter validation owns the coverage conversation.
Second, follow the site-of-service money. If office-based practices are gaining 7% to 10% while facility-based practices lose 11%, the office is where procedure volume migrates, and office-suitable form factors (recharge-free, minimally invasive, temporary implants) get a structural tailwind that has nothing to do with clinical merit. Abbott’s Eterna at five charges per year and SPR’s 60-day PNS are aligned with this. Bulky, facility-dependent systems are not.
Third, treat the ten-year real-world evidence demand as a moat rather than a tax. Incumbents with deep trial portfolios are advantaged by MDR-style evidence requirements. Fund the registries.
The first decision is setting, and it is now a financial decision rather than a clinical one. Practices with material facility-side exposure should model the roughly 11% reduction against the roughly 7% to 10% office-based increase and ask honestly whether the ASC still earns its capital. This inverts a decade of strategic orthodoxy.
The second is measurement. The Ambulatory Specialty Model scores individual clinicians on cost and quality for low back pain from 2029, and mandatory participants are exempted from MIPS. Practices that begin capturing function outcomes in 2026 will be scored on four years of data. Practices that start in 2028 will be scored on guesswork.
The third is revenue architecture. Time-based codes were deliberately spared the efficiency adjustment, and CY2026 created new RPM and RTM codes for 2 to 15 days of data with a lower clinical time threshold. Chronic pain is, by definition, longitudinal. A practice that only bills for procedures is leaving the one growing reimbursement line untouched.
The fourth is the cash-pay layer. Not as a pivot, but as a hedge. Revenue with no payer attached is the only revenue CMS cannot reprice, and it is growing at roughly 12% per year. The caution is real: QC Kinetix proved that scaling a marketing-led cash-pay model without clinical depth produces a 28.6% revenue collapse. The layer works when it is physician-delivered and evidence-based. It fails when it is a sales funnel.
This section is written against the buyer profiles that define the premium end of the sector, which ISPW articulates as clearly as anyone in it: the Active Ageless Athlete and the Health-Conscious Professional. Both are affluent, analytical, and burned. They have already tried cortisone. They have already been told to rest. They are not shopping for a procedure; they are shopping for someone who will not waste another year of their life.
Four implications follow.
Channel-wise: the concierge and out-of-town pathways are structurally underused in this segment. An affluent patient will fly for a physician they trust and will not fly for a franchise. Geographic catchment is a variable, not a constraint.
Pain management is one of the last genuinely fragmented specialties, with fewer than 20 platforms against 60-plus gastroenterology deals since 2021. The lag was rational: reimbursement volatility and opioid-era optics. Both are still true, and the 2026 fee schedule made the first one worse. The window is real, but the diligence question has changed.
The question is no longer "how many procedures does this practice do?" It is "what share of this practice’s revenue survives the ASM." Underwrite site-of-service mix, cash-pay percentage, time-based code capture, and whether the practice can evidence function outcomes. A facility-heavy, procedure-volume practice bought on a 2025 multiple is a 2029 problem. Watch also the state-level MSO and CPOM scrutiny, which is the most credible near-term threat to the structure on which the whole thesis depends.
Moderate-to-strong growth, with a base case of approximately $107 billion by 2031 from an estimated $78 billion in 2026, a 6.5% CAGR. Demand is not the variable. One in four American adults has chronic pain, and the number is rising. The population most affected is the population growing fastest, and the pharmacological alternative has been discredited as first-line therapy for a decade.
What is genuinely uncertain is who captures the value. The sector’s 2026 to 2031 arc will be written by three forces that have almost nothing to do with clinical innovation: a fee schedule that pays the office and punishes the facility, a mandatory payment model that scores outcomes rather than volume from 2029, and a self-pay segment growing at twelve percent a year that no payer controls and no regulator has finished defining.
The practices and companies that thrive will be the ones that read those three forces as one instruction. Move care to where it is cheapest to deliver and best paid, prove the outcome rather than asserting it, and build a revenue line that does not depend on anyone’s permission. That is not a growth strategy. It is a survival strategy that happens to also be the growth strategy.
